You are herePharma News

Pharma News

Relief India Trust NGO: Fighting Thalassemia through Human Touch

(Business Wire India; 18th July, 2014); For three-year-old Sneha, life is a struggle in continuity. A patient of Thalassemia major, Sneha battles death every single day. Her parents, despite being advised to undergo medical tests to diagnose her condition when she was in her mother’s womb, chose to disregard this warning. Now, this unawareness and lack of understanding might cost them dear. Unfortunately, they lost their four-year-old son two years ago due to the same blood disorder.

Possibly new generation of anti-diabetic drug - stops diabetes in its tracks and reverses insulin insensitivity with no side effects

(17th July, 2014); Researchers from Salk discovered new and more effective diabetic drug which could lead for safe & new generation of anti-diabetic drugs. They injected single injection of the protein FGF1 which is enough to restore blood sugar levels to a healthy range for more than two days.

India topped in antibiotics use across the world

(15th July, 2014); Study published by researchers shown that use of antibiotics is increasing day by day across the world. Unsurprisingly India is the largest consumer of antibiotics in 2010. As per study, use is not being effectively monitored by health officials, from doctors to hospital workers to clinicians, noted the researchers. Consequently, antibiotic use is both rampant and less targeted. That reality is driving antibiotic resistance at an unprecedented rate.

Dengue Vaccine to reach phase 3 clinical testing for first time

(15th July, 2014); The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet.

New bulk drug centre to establish at NIPER, Hyderbad

(14th July, 2014); NIPER, Hyderbad is all set to develop National Centre for Research & Development in Bulk Drug (NCRDBD) for filling up gap in Research and Development in bulk drugs. The over all project costs around more than 52 crore rupees and with an operating cost of over 37 crore rupees for five years.

Drinking alocohol provides no heart benefits - dissent prior studies

(11th July, 2014); Recent research asking questions to prior studies which stated that one drink per day may promote cardiovascular health. As per recent research published in The BMJ led by the Perelman School of Medicine at the University of Pennsylvania, reducing the amount of alcoholic beverages consumed, even for light-to-moderate drinkers, may improve cardiovascular health, including a reduced risk of coronary heart disease, lower body mass index (BMI) and blood pressure.

HIV reappeared in child seemingly cured

(11th July, 2014); The child known as the “Mississippi baby”—an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall—now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric HIV specialist and researchers involved in the case.

Unichem Laboratories to appeal the decision of European Commission

(10th July, 2014); On 9th July 2014, the European Commission (the EU’s top competition regulator) decided to impose a wholly unjustified fine on Niche /Unichem (jointly and severally) contending that it had acted in breach of EU Antitrust Rules. The European Commission reached this conclusion because its subsidiary, Niche Generics Ltd (Niche), agreed to settle financially crippling patent litigation with Laboratories Servier (Servier) at the beginning of 2005.

Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis

(Business Wire India; 10th July, 2014); Celgene Corporation (NASDAQ:CELG) announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS (Assessment of SpondyloArthritis international Society) 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing.

Deliberations and recommendations made by the Apex Committee for supervising clinical trials

(9th July, 2014); The meeting of the apex committee held on 17-06-2014 under the chairmanship secretary  of health and family welfare for supervising clinical trials (CTs) on new chemical entities in the light of directions of the honorable supreme court of India dated 03.01.2013